Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Improved Safety and Efficacy with Standardised Plasmapheresis Protocol

Athira Unnikrishnan, MD, Abdullah Mohammad Khan, MBBS,MSc, Jameel Muzaffar, MD, Julia Close, MD, Jennifer M. Duff, MD, Priya Gopalan, MD PhD, Martina C. Murphy, MD

Blood (2017) 130 (Supplement 1): 5591.

https://doi.org/10.1182/blood.V130.Suppl_1.5591.5591

Published: 2017

Journal Articles

Characteristics of Light Chain Deposition Disease (LCDD) and Factors Affecting Outcome after Treatment

Jameel Muzaffar, MD, Abdullah Mohammad Khan, MBBS,MSc, Athira Unnikrishnan, MD, Preeti Narayan, MD, Dara Wakefield, MD, Jan S Moreb, MD

Blood (2017) 130 (Supplement 1): 5513.

https://doi.org/10.1182/blood.V130.Suppl_1.5513.5513

Published: 2017

Journal Articles

New Salvage Vincristine, BCNU, Cyclophosphamide, Prednisone (VBCP) Chemotherapy for Relapsed/Refractory Multiple Myeloma in the Modern Era: A Case Series

Abdullah Zubayer Khan, FCPS, Jameel Muzaffar, MD, Lazarus K Mramba, PhD, Jan S Moreb, MD

Blood (2017) 130 (Supplement 1): 5412.

https://doi.org/10.1182/blood.V130.Suppl_1.5412.5412

Published: 2017

Journal Articles

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Rashid Z Khan, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Xenofon Papanikolaou, MD, Caleb K Stein, MS, Adam Rosenthal, Christoph Heuck, MD, Frits van Rhee, MD PhD, Jameel Muzaffar, MD, Maurizio Zangari, MD, Clyde Bailey, Phillip Farmer, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 5770.

https://doi.org/10.1182/blood.V124.21.5770.5770

Published: 2014

Journal Articles

Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions

Bart Barlogie, MD, PhD, Emily Hansen, MS, Sarah Waheed, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Joshua Epstein, DSc

Blood (2013) 122 (21): 3123.

https://doi.org/10.1182/blood.V122.21.3123.3123

Published: 2013

Journal Articles

Characteristics and Prognosis Of IgM Multiple Myeloma

Shebli Atrash, MD, Qing Zhang, PhD, Xenofon Papanikolaou, MD, Christoph Heuck, MD, Aziz Bakhous, M.D., Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1881.

https://doi.org/10.1182/blood.V122.21.1881.1881

Published: 2013

Journal Articles

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Bart Barlogie, MD, PhD, Alan Mitchell, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Monica Grazziutti, MD, Alejandro Restrepo, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Senu Apewokin, MD, Shebli Atrash, MD, Aziz Bakhous, M.D., Sajjad Haider, MD, Surachit Kumar, MD, Jameel Muzaffar, MD, Zainab Shahid, MD, John Crowley, PhD

Blood (2012) 120 (21): 1850.

https://doi.org/10.1182/blood.V120.21.1850.1850

Published: 2012

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Joshua Epstein, DSc, Adam Rosenthal, Christoph Heuck, MD, Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Nathan M Petty, Clyde Bailey, Antje Hoering, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 195.

https://doi.org/10.1182/blood.V120.21.195.195

Published: 2012

Journal Articles

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Sarah Waheed, MD, Monica Grazziutti, MD, Alejandro Restrepo, MD, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bijay Nair, MD, Antje Hoering, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 1962.

https://doi.org/10.1182/blood.V120.21.1962.1962

Published: 2012

Journal Articles

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Al-Ola Abdallah, MD, Shebli Atrash, MD, Jameel Muzaffar, MD, Nisar Ahmad, MD, Sajjad Haider, MD, Monica Grazziutti, MD, Senu Apewokin, MD, Zainab Shahid, MD, Alejandro Restrepo, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 2925.

https://doi.org/10.1182/blood.V120.21.2925.2925

Published: 2012

Journal Articles

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Sajjad Haider, MD, Lakshmikanth Katragadda, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Muhammad R Akbar, MD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, Ph.D, Elias J. Anaissie, MD

Blood (2011) 118 (21): 4526.

https://doi.org/10.1182/blood.V118.21.4526.4526

Published: 2011

NARROW

Improved Safety and Efficacy with Standardised Plasmapheresis Protocol

Characteristics of Light Chain Deposition Disease (LCDD) and Factors Affecting Outcome after Treatment

New Salvage Vincristine, BCNU, Cyclophosphamide, Prednisone (VBCP) Chemotherapy for Relapsed/Refractory Multiple Myeloma in the Modern Era: A Case Series

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions

Characteristics and Prognosis Of IgM Multiple Myeloma

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only